Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease

Neurology

Volumn 58, Issue 8, 2002, Pages 1182-1188

  Scarmeas, N ^a,b   Brandt, J ^c   Albert, M ^d   Devanand, D P ^a,b   Marder, K ^a,b   Bell, K ^a,b   Ciappa, A ^a   Tycko, B ^a   Stern, Y ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; COGNITION; DELUSION; DEPRESSION; DISEASE DURATION; EDUCATION; ETHNOLOGY; FEMALE; FOLLOW UP; GENOTYPE; HALLUCINATION; HUMAN; ILLUSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; SEX; SYMPTOMATOLOGY;

EID: 0037161280     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.8.1182     Document Type: Article

References (62)

1. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type
2. The course of psychopathologic features in mild to moderate Alzheimer disease
3. Behavioral changes associated with different apolipoprotein E genotypes in dementia
4. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
5. The impact of dementia on the family
6. Antipsychotic medications and the elderly: Effects on cognition and implications for use
7. Predicting time to nursing home care and death in individuals with Alzheimer disease
8. Predictors of disease course in patients with probable Alzheimer's disease
9. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: Prospective analyses from the Predictors Study
10. APOE-related frequency of cognitive and noncognitive symptoms in dementia
11. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease
12. Apolipoprotein E: Non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease
13. The apolipoprotein E epsilon 4 allele is associated with increased behavioral disturbance in Alzheimer's disease
14. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer's disease
15. Apolipoprotein E: Non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease
16. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: Relation to apolipoprotein E polymorphism
17. Analysis of phenotype in Alzheimer's disease (AD) associated with apolipoprotein E (APOE) alleles
18. Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+
19. Depression, delusions, and hallucinations in Alzheimer's disease: No relationship to apolipoprotein E genotype
20. Factors associated with psychotic symptoms in Alzheimer's disease
21. The apolipoprotein E epsilon 4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease
22. Psychotic symptoms and apolipoprotein E genotypes in an elderly population
23. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease
24. Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease
25. No association between apolipoprotein E genotype and late-onset depression in Alzheimer's disease
26. Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease
27. A longitudinal study of apolipoprotein-E genotype and depressive symptoms in community-dwelling older adults
28. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease
29. Multicenter study of predictors of disease course in Alzheimer disease (the "Predictors Study"). I. Study design, cohort description, and intersite comparisons
30. Multicenter study of predictors of disease course in Alzheimer disease (the "Predictors Study"). II. Neurological, psychiatric, and demographic influences on baseline measures of disease severity
31. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
32. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician
33. Depression, intellectual impairment, and Parkinson disease
34. Modified Mini-Mental State Examination: Validity and reliability
35. Premorbid history of major depression and the depressive syndrome of Alzheimer's disease
36. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects
37. Restriction isotyping of human apolipoprotein A-IV: Rapid typing of known isoforms and detection of a new isoform that deletes a conserved repeat
38. The Columbia University Scale for Psychopathology in Alzheimer's disease
39. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease
40. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics
41. Influence of education and occupation on the incidence of Alzheimer's disease
42. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis
43. Heterogeneity in dementia of the Alzheimer type: Evidence of subgroups
44. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease
45. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease
46. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein
47. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease
48. Neuropathologic and neurochemical correlates of psychosis in primary dementia
49. Major depression in primary dementia. Clinical and neuropathologic correlates
50. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele
51. Apolipoprotein E, memory and Alzheimer's disease
52. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
53. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease
54. A SPECT study of delusions in Alzheimer's disease
55. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes
56. SPECT and MRI analysis in Alzheimer's disease: Relation to apolipoprotein E epsilon 4 allele
57. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
58. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease
59. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
60. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo- controlled trial